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January, 2004, administration of measles
vaccine was recommended between 12
and 24 months of age, instead of
between 12 and 15 months when chil-
dren have the greatest risk of contracting
measles. There is no established system
to check vaccination status on entry to
the school systems.
Strong political and social desire has to
be inspired, and vigorous educational
campaigns for policy makers and the
general public are required. If there are
clear strategies and prioritisation on vac-
cine policies, and a strong will to combat
the disease, measles in Japan can be con-
trolled. The great success of near elimi-
nation of measles on the American
continents is strong encouragement.5 It
is time for the Japanese government to
regain leadership on this issue.
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products, the prices are much higher
than ﬁrst-line ﬁxed-dose combinations.
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First-line and 
second-line
antiretroviral therapy
The results of the 2NN study (April 17,
p 1253)1 confirm that nevirapine com-
bined with stavudine and lamivudine is a
In his Commentary on the 2NN study,
Andrew Carr1 recommends that nevi-
rapine and protease inhibitors should
not be co-administered with rifampicin,
and that the efavirenz dose should be
adjusted to 800 mg/day when given
with rifampicin. This advice goes along
with recommendations in the recent
past, which were based on pharmaco-
kinetic data showing that rifampicin
interferes with concentrations of nevi-
rapine and protease inhibitors when
they are co-administered.
However, two recent studies, albeit
small, showed a favourable HIV clinical
and virological response in patients who
received concurrent nevirapine and
rifampicin.2,3 On the basis of these data,
updated recommendations leave open
the option of possible co-administration
of these two drugs, with close clinical
and virological monitoring.4,5 Optional is
an increase in nevirapine dose (such as
300 mg twice daily),4 probably in
patients who weigh 60 kg or more. As
for efavirenz, the co-administered dose
could be reduced to the standard 600
mg/day if 800 mg/day is intolerable.4
valid option for a ﬁrst-line antiretroviral
therapy. This information is crucial for all
clinicians working in developing coun-
tries, since this combination is not only
the cheapest but also the only ﬁxed-dose
combination to date that has been 
prequaliﬁed by WHO.2 Fixed-dose com-
binations reduce the pill burden,
increasing ease of use, minimising the
risk of drug resistance, and facilitating
drug supply.3
In his accompanying Commentary,4
Andrew Carr supports the importance
of this fixed-dose combination. Two
additional advantages of nevirapine
over efavirenz for the developing world
not noted in the Commentary are that it
can be used in pregnant women and in
children younger than age 3 years. Carr’s
claim that efavirenz co-formulations are
available is unfortunately ahead of its
time: technical difﬁculties mean that
such efavirenz-containing combina-
tions are unlikely to be produced for at
least 2 years; intellectual property con-
straints could delay this even further.
Currently, only two co-formulations
based on non-nucleoside reverse-tran-
scriptase inhibitors are available in
developing countries, and both contain
nevirapine.
There might be concern over increased
toxicity associated with use of nevi-
rapine-based regimens, particularly in
countries with no or little laboratory
monitoring capacity. However, Médecins
Sans Frontières (MSF) has been using
nevirapine-based first-line regimens
since mid-2001, mainly as a fixed-dose
triple combination of stavudine, lamivu-
dine, and nevirapine. Of more than 5000
patients currently treated with nevi-
rapine by MSF, fewer than 2% have had
to stop due to hepatotoxicity.5 The
median CD4 count in this cohort at base-
line was 67 per L (IQR 19–139), which
could explain the relatively low preva-
lence of hepatic injury in this very
immunosuppressed group.
Our experience is that this nevirapine-
based first-line regimen is safe,
affordable, and convenient to use. Our
major concern is to find a second-line
regimen, since there are no fixed-dose
combinations for second-line treatment
to date. Furthermore, because second-
line drugs are mostly monopoly
